Cogent Biosciences, Inc. research snapshot
COGT AI stock analysis currently sees Cogent Biosciences as a pre-commercial biotechnology company with bezuclastinib NDA submissions in Advanced Systemic Mastocytosis and GIST, a PDUFA date of November 30, 2026, and positive Phase 3 data from both the APEX and PEAK trials. At the July 12, 2026 cutoff, COGT traded near $38.87 with a verified market capitalization of $6.64 billion. The core tension is that the clinical data are strong and the commercial opportunity is real, while the company has zero product revenue, a trailing twelve-month net loss of approximately $329 million, increasing operating cash burn, and $643 million in net cash providing a runway. This page is informational only and not investment advice.
Current price
$38.87
Market cap
$6.64 billion
AI score
42 / 100
Rating
Bezuclastinib NDA momentum is strong, but the company remains pre-revenue with binary regulatory and commercial risk
Trend status
Above the 50-day and 200-day moving averages, near 52-week highs
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Cogent is a pre-revenue precision oncology company developing bezuclastinib for genetically defined diseases. The business quality is unproven: no approved products, no revenue, and no commercial infrastructure yet. Clinical execution has been strong, but business quality cannot be assessed until there is a commercial track record. | Low |
| Moat | The moat is hypothetical. Bezuclastinib targets KIT exon 17 mutations with selectivity that differentiates it from older multikinase inhibitors. If approved, patents, regulatory exclusivity, manufacturing know-how, and prescriber relationships could create barriers. However, the moat is narrow until commercial scale is achieved. | Low |
| Management | CEO Daniel Welch and the management team have guided bezuclastinib through Phase 3 success and NDA submission. The next capital-allocation test is balancing commercial launch investment, pipeline expansion, and cash management to reach profitability without excessive dilution. | Medium |
| Financial trend | COGT has zero revenue and a widening net loss trajectory: -$256 million in FY2024, -$329 million in FY2025, and a -$97 million loss in Q1 2026 alone. Operating cash burn was -$87 million in Q1 2026. The trend is deteriorating and will continue until product revenue begins. | High |
| Valuation | At $38.87, COGT has a $6.64 billion market cap with zero revenue and negative earnings. P/E and P/S are not meaningful. P/B is 10.12x, reflecting the market pricing future commercial cash flows rather than current book value. The $643 million net cash position provides approximately 2 years of runway at current burn rates. | Medium |
| Technical trend | COGT was trading at $38.87, within 11% of its 52-week high of $43.73 and well above its 52-week low of $10.38. The stock is above both its 50-day and 200-day moving averages, showing a strong uptrend driven by positive clinical data and NDA milestones. | Medium-high |
| Risk level | Risk is very high. COGT faces binary regulatory decisions (PDUFA November 30, 2026 for GIST), commercial launch execution, pricing and reimbursement uncertainty, competition from approved therapies, cash burn, potential dilutive financing, and clinical-stage pipeline risk. | High |
| AI confidence | Reported financial and clinical data are well documented, but AI cannot know FDA decisions, pricing, market adoption, or the outcome of future trials. | High data confidence |
| Investment certainty | Investment certainty is low because the entire valuation depends on regulatory approval and commercial adoption of a drug that has not yet been approved or sold. The wide range of analyst price targets ($20 to $67) illustrates the uncertainty. | Low |
COGT AI stock forecast
The COGT AI stock forecast uses scenarios instead of a promised price. Because COGT is pre-revenue with no positive EPS, the three-year model uses illustrative peak sales assumptions for bezuclastinib in GIST and AdvSM, with probability-adjusted net present value. These scenarios are valuation frameworks, not predictions, because FDA decisions, pricing, market share, and competition remain highly uncertain.
$55 to $70
More likely if bezuclastinib is approved in both GIST and AdvSM with broad labels, pricing supports meaningful peak sales, commercial launch execution is strong, reimbursement is secured, PDUFA milestone (Nov 30, 2026) passes without delay, and cash management extends runway without dilutive financing.
$30 to $45
More likely if bezuclastinib is approved in at least one indication with a moderate label, initial commercial uptake is steady but not exceptional, competition from approved therapies limits market share, and ongoing cash burn requires some additional financing.
$10 to $20
More likely if a Complete Response Letter or significant label limitation delays or restricts approval, clinical data are questioned, pricing or reimbursement disappoints, competition captures more share than expected, or cash burn forces dilutive financing that transfers value away from current shareholders.
COGT AI technical analysis
COGT AI technical analysis uses the July 10, 2026 Barchart and MarketBeat market snapshots. The static page does not fetch live market data. The price reference of $38.87 was above the 50-day and 200-day moving averages, near the upper end of the 52-week range, indicating a strong uptrend supported by positive clinical milestones.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $38.87 | Quote snapshot used for the July 12, 2026 analysis and market-cap calculation. |
| Near support | $31 to $32 | The 50-day moving average area. A live chart should confirm whether this zone holds on pullbacks. |
| Secondary support | $24 to $26 | The 200-day moving average zone, which acted as resistance in early 2026 before the stock broke higher. |
| 52-week high resistance | $43.73 | The all-time high. A sustained breakout above this level would open a new price range. |
| Momentum | RSI near 70 (overbought) | Barchart reported RSI approaching 70 at the July 10 close. The stock has moved from overbought territory, signaling potential mean reversion. |
| Volume | 3.18 million average shares | MarketBeat reported 30-day average volume of 3.18 million shares. Volume spikes around clinical data readouts and regulatory milestones. |
| Volatility | Beta 0.34, event-driven | Reported beta was below one, but binary biotech events can produce sharp gaps that beta does not capture. |
| Short interest | 10.24% of float | Short interest is elevated at 10.24%, reflecting significant bearish positioning. This can add volatility around binary events. |
| Invalidation | Sustained close below $31 | A sustained close below the 50-day moving average area would weaken the uptrend and should trigger a review of fundamentals. |
COGT AI trading strategy
The COGT AI trading strategy is a research and risk-control framework, not a personalized recommendation. It combines live chart confirmation with PDUFA milestones, clinical data events, cash position updates, and financing announcements.
COGT is driven by binary regulatory and clinical events. The next major catalyst is the PDUFA date of November 30, 2026 for bezuclastinib in GIST. Monitor NDA review progress, FDA advisory committee meetings, and any clinical data updates.
Binary event risk means position sizing must account for the possibility of 30-50% gap moves in either direction. Tight stops are unreliable around FDA decisions.
If COGT holds above the 50-day moving average near $31-$32 and continues to trend higher, a trend-following approach can be considered. Confirm price action with positive regulatory progress and no cash runway deterioration.
A sustained close below the 50-day average or a failed PDUFA event would invalidate the trend. Size for gap risk rather than relying on a tight stop.
Track the PDUFA timeline, FDA labeling decisions, commercial launch plans, cash and investment balance, operating burn rate, any new equity or debt financing, bezuclastinib pricing in approved indications, and competitor developments.
Reduce confidence if cash burn accelerates without a corresponding increase in near-term approval probability, if the FDA issues a CRL, or if dilutive financing is announced at unfavorable terms.
Investment research summary
Cogent Biosciences is a precision oncology company developing bezuclastinib, a selective KIT D816V inhibitor, for genetically defined diseases including Advanced Systemic Mastocytosis and Gastrointestinal Stromal Tumors. Customers and payers will pay if the drug is approved, gains favorable labeling, achieves broad reimbursement, and demonstrates superior efficacy or tolerability versus existing therapies.
The moat is potential rather than proven. If approved, bezuclastinib would benefit from regulatory exclusivity, patent protection, selective KIT inhibition differentiated from multikinase inhibitors, and first-mover data in AdvSM. The moat can narrow if competing KIT inhibitors, improved therapies, or generics enter the market.
The thesis fails if the FDA issues a Complete Response Letter, if the label is significantly narrower than expected, if pricing or reimbursement is unfavorable, if commercial launch execution is slow, if competition erodes market share, if cash burn requires dilutive financing, or if pipeline candidates fail in clinical trials.
Management has advanced bezuclastinib through Phase 3 success in two indications and NDA submission. The capital-allocation test ahead is whether launch investment, R&D spending, and cash management can reach profitability without excessive shareholder dilution. The 80-person team is lean for a commercial launch.
Precision oncology and targeted therapy for genetically defined diseases represent a lasting industry trend. Both GIST and AdvSM have established treatment paradigms with room for improved therapies. The opportunity is real but constrained by patient population size, pricing pressure, and competition from both approved and pipeline therapies.
The market is pricing COGT at $6.64 billion based on expected future approval and commercial cash flows rather than current earnings or revenue. Margin of safety is limited until approval, label, pricing, and initial commercial data provide concrete evidence of the revenue trajectory.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| COGT price | $38.87 | MarketBeat quote snapshot | July 12, 2026 |
| Market capitalization | $6.64 billion, verified as $38.87 x 170.87 million shares | financial_rigor.py and MarketBeat | July 12, 2026 |
| Cash and investments | $866 million at March 31, 2026 ($241M cash + $625M short-term investments) | MarketBeat financials (balance sheet) | July 12, 2026 |
| Long-term debt | $223 million at March 31, 2026; net cash of $643 million | MarketBeat financials (balance sheet) | July 12, 2026 |
| FY2025 net loss | -$329 million, widening from -$256 million in FY2024 | MarketBeat financials (income statement) and SEC filings | July 12, 2026 |
| Q1 2026 net loss | -$97 million; operating cash use -$87 million | MarketBeat financials (cash flow statement) | July 12, 2026 |
| Shares outstanding | 170.87 million at March 31, 2026 | MarketBeat financials | July 12, 2026 |
| Valuation math | P/E and P/FCF are not meaningful with negative TTM EPS and free cash flow; P/B about 10.12x; ROE -57.19% | financial_rigor.py valuation verification | July 12, 2026 |
| Technical inputs | Near 52-week high of $43.73, 52-week low $10.38, RSI near 70, 30-day average volume 3.18M, short interest 10.24% | Barchart and MarketBeat statistics | July 12, 2026 |
| Analyst consensus | Moderate Buy, 14 analysts, price target range $20.00 to $67.00, consensus $43.73 | MarketBeat analyst forecasts | July 12, 2026 |
This COGT AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public filings, clinical trial disclosures, quote snapshots, technical data, and third-party sources as of July 12, 2026. They may be wrong, incomplete, or outdated after new clinical data, FDA decisions, commercial updates, financing events, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
